---
title: 'INSPIRED Symposium Part 4A: Access to CAR T cell Therapy in Unique Populations
  with B-cell Acute Lymphoblastic Leukemia'
date: '2023-10-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37821078/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231012180749&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Tisagenlecleucel's approval in children with B-cell acute lymphoblastic
  leukemia (B-ALL) was based on the phase 2 ELIANA trial, a global registration study.
  The ELIANA trial, however, excluded specific subsets of patients facing unique challenges
  and did not include enough patients to adequately evaluate outcomes in rare sub-populations.
  Since commercialization of tisagenlecleucel, data has become available that supports
  therapeutic indications beyond the specific cohorts previously eligible ...
disable_comments: true
---
Tisagenlecleucel's approval in children with B-cell acute lymphoblastic leukemia (B-ALL) was based on the phase 2 ELIANA trial, a global registration study. The ELIANA trial, however, excluded specific subsets of patients facing unique challenges and did not include enough patients to adequately evaluate outcomes in rare sub-populations. Since commercialization of tisagenlecleucel, data has become available that supports therapeutic indications beyond the specific cohorts previously eligible ...